Apoptosis is a highly regulated form of programmed cell death characterized by cell shrinkage, chromatin condensation, and fragmentation into membrane-bound bodies. Two main pathways exist: the extrinsic (death receptor) pathway initiated by external signals and the intrinsic (mitochondrial) pathway triggered by cellular stress, both converging on executioner caspases. Defective apoptosis contributes to cancer, while excessive apoptosis underlies many degenerative diseases.
Trace the extrinsic pathway from death receptor ligation through adaptor proteins to caspase-8, and the intrinsic pathway from cellular stress through mitochondrial membrane permeabilization to caspase-9. Examine Bcl-2 family proteins as gatekeepers.
Apoptosis is not necrosis—it generates no inflammation and involves active energy expenditure. Cancer cells often evade apoptosis by mutating p53 or overexpressing anti-apoptotic proteins like Bcl-2.
From your prerequisite work, you already understand that cells die in two fundamentally different ways: necrosis is uncontrolled death that spills cellular contents and triggers inflammation, while apoptosis is an orderly, programmed dismantling. What this topic unpacks is the molecular machinery that executes apoptosis and how the cell decides — often in a matter of minutes — whether to live or die. This decision machinery is extraordinarily relevant to disease: too little apoptosis allows cancer; too much drives neurodegeneration.
The extrinsic pathway is triggered from outside the cell. Death ligands such as Fas-L or TNF-α bind to death receptors on the cell surface (Fas/CD95, TNFR1). These receptors contain a cytoplasmic "death domain" that recruits adaptor proteins — most importantly FADD — which in turn recruit and activate procaspase-8. Caspase-8 is an initiator caspase: it does not execute death itself but activates the downstream executioner caspases (caspase-3, -6, -7). This pathway is how cytotoxic T lymphocytes kill virally infected cells — the immune system literally hands infected cells a death sentence through Fas-L.
The intrinsic pathway is triggered by internal damage: DNA double-strand breaks, hypoxia, oxidative stress, or oncogene activation. The signal converges on the Bcl-2 family of proteins, which function as the master switch at the mitochondrial outer membrane. The family has two opposing camps: anti-apoptotic members (Bcl-2, Bcl-xL) hold the membrane intact; pro-apoptotic members (Bax, Bak, and the BH3-only sensors like Bid, Bim, PUMA) permeabilize it. When pro-apoptotic signals overwhelm anti-apoptotic ones, Bax and Bak oligomerize and punch pores in the outer mitochondrial membrane — releasing cytochrome c into the cytoplasm. Cytochrome c binds Apaf-1, which recruits and activates procaspase-9, forming the apoptosome complex. Caspase-9 then activates the same executioner caspases as the extrinsic pathway. Both routes converge on caspase-3, which systematically dismantles the cell: cleaving structural proteins, activating endonucleases that fragment DNA at internucleosomal linker regions (producing the "DNA ladder" pattern on gel electrophoresis), and exposing phosphatidylserine on the outer leaflet of the plasma membrane as an "eat me" signal for phagocytes.
The reason cancer so frequently involves apoptosis evasion now becomes mechanically clear. p53 is a transcription factor that senses DNA damage and upregulates pro-apoptotic BH3-only proteins like PUMA and Noxa — it pushes the Bcl-2 balance toward death. When p53 is mutated (as in >50% of cancers), damaged cells survive and accumulate further mutations. Bcl-2 overexpression — first discovered in follicular lymphoma via the t(14;18) translocation — directly protects mitochondria from permeabilization, blocking the intrinsic pathway entirely. Modern cancer drugs like venetoclax are BH3-mimetics: they bind the hydrophobic groove of Bcl-2 and displace trapped pro-apoptotic proteins, effectively restarting the death program that cancer cells have silenced.